| 22.42 Delayed Data As of 6:30pm ET |  -0.88 / -3.78%Today’s Change | 16.42 Today|||52-Week Range 62.25 | -47.59% Year-to-Date |
The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
| 5 Leveraged/Inverse ETFs That Are Up 20% Plus So Far in Q2 May 23 / Zacks.comZAK - Paid Partner Content |
| 1 month | +2.17% | 3 years | -61.60% | |
| 3 months | -1.62% | 5 years | -- | |
| 1 year | -22.00% | Since inception | -51.28% |
| Previous close | $23.30 |
| Open day’s range | 22.01 – 23.00 |
| Net asset value (NAV) | 22.62 (05/22/2019) |
| Daily volume | 2,834,074 |
| Average volume (3 months) | 4,302,409 |
| LABD | Category | |
|---|---|---|
| Performance 5-yr return | -- | -29.79% |
| Expense Gross exp ratio | 1.13% | 1.98% |
| Risk 5 year sharpe ratio | -- | -- |
| Net assets | $122.1M | $9.9M |
| Average market cap | -- | -- |
| Average P/E | -- | -- |
| Dividend / Share | -- | 47.05% |
| Business service | -- |
| Consumer goods | -- |
| Consumer service | -- |
| Energy | -- |
| Financial service | -- |
| Holdings not available. |
